Prescient funds PTX-100 beyond key December review

$6 million raise extends PTX-100 funding

Prescient Therapeutics (ASX:PTX) has secured approximately $6 million to keep its lead cancer program moving beyond the next major clinical decision point. The raise comprises approximately $4.8 million from the Share Purchase Plan and a further $1.2 million through a shortfall placement to sophisticated and professional investors.

The figures in the announcement contain an apparent unit error, describing the individual amounts as “million” amounts despite the stated combined total. Read against that total, the SPP contribution was $4,798,108 and the placement raised $1,203,699.96. Both components were priced at $0.065 per share, with around 18.5 million new shares expected from the placement alone.

December review becomes the immediate clinical checkpoint

The fresh capital is intended to strengthen Prescient’s cash position and fund PTX-100 beyond the first Dose Optimisation Committee review, scheduled for December 2026. The committee is expected to recommend which dose should move forward and provide guidance on whether the study continues, meaning the raise supports development through a decision that remains dependent on clinical results.

PTX-100’s Phase 2 study in relapsed or refractory cutaneous T-cell lymphoma has enrolled 20 evaluable patients, split between two dosing arms, against a planned total of 40. Recruitment is continuing globally. Prescient says the program has shown encouraging efficacy and safety in a completed Phase 1b expansion cohort, but the announcement does not provide new efficacy data from the current Phase 2 study.

Phase 2b ambition still depends on study data

Chief executive James McDonnell said the raise would fund PTX-100 through Phase 2a and create an opportunity to advance into a Phase 2b study with registrational potential. He also identified two possible routes to commercialisation: Prescient bringing the therapy to market itself or pursuing a partnering outcome. Those remain stated development possibilities rather than committed next steps.

PTX-100 has US FDA Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for adults with relapsed or refractory mycosis fungoides. The company’s broader pipeline includes the preclinical OmniCAR, CellPryme-A and CellPryme-M platforms, but the new funding is explicitly tied to continued PTX-100 development. The SPP and placement shares are expected to be allotted on or around 30 September, while the December committee review is the more consequential milestone for the program.